Biotech News
Related news
IMTXImmatics2026-08-25 11:00 EST
Immatics Announces $150 Million Underwritten Offering
IMTXImmatics2026-08-18 11:00 EST
Immatics Announces Second Quarter 2026 Financial Results and Business Update
ERASErasca2026-09-10 12:00 EST
Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium
FATEFate Therapeutics2026-09-16 11:00 EST
Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026
KYMRKymera2026-09-01 11:00 EST
Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses
ELVNEnliven Therapeutics2026-08-31 22:05 EST
Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
FATEFate Therapeutics2026-10-01 11:00 EST
Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences
ELVNEnliven Therapeutics2026-09-03 20:05 EST
Enliven Therapeutics to Present at Upcoming Investor Conferences
BMEABiomea Fusion2026-09-03 12:00 EST
Biomea Fusion to Participate in Upcoming Investor Conferences
RLAYRelay Therapeutics2026-09-01 20:46 EST
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
Immatics
TCR-Based Solid Tumor Immunotherapy Immatics develops engineered T-cell therapies and TCR bispecifics directed against intracellular cancer targets presented by HLA molecules. PRAME Franchise The company has built multiple modalities around PRAME, a target expressed across more than 50 cancers. Anzu-cel Anzu-cel is an autologous...
Recent company news
IMTXImmatics2026-08-25 11:00 EST
Immatics Announces $150 Million Underwritten Offering
IMTXImmatics2026-08-18 11:00 EST
Immatics Announces Second Quarter 2026 Financial Results and Business Update
IMTXImmatics2026-07-17 14:25 EST
Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026
IMTXImmatics2026-06-01 12:00 EST
Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting
IMTXImmatics2026-05-31 13:00 EST
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
Stock data
- Close
- 8.44 USD
- Market cap
- 1.37B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States